has been cited by the following article(s):
[1]
|
Dosimetry in Lu-177-PSMA-617 prostate-specific membrane antigen targeted radioligand therapy: a systematic review
Nuclear Medicine Communications,
2022
DOI:10.1097/MNM.0000000000001535
|
|
|
[2]
|
Dosimetry in Lu-177-PSMA-617 prostate-specific membrane antigen targeted radioligand therapy: a systematic review
Nuclear Medicine Communications,
2022
DOI:10.1097/MNM.0000000000001535
|
|
|
[3]
|
Dosimetry in Lu-177-PSMA-617 prostate-specific membrane antigen targeted radioligand therapy: a systematic review
Nuclear Medicine Communications,
2022
DOI:10.1097/MNM.0000000000001535
|
|
|
[4]
|
Dosimetry in Lu-177-PSMA-617 prostate-specific membrane antigen targeted radioligand therapy: a systematic review
Nuclear Medicine Communications,
2022
DOI:10.1097/MNM.0000000000001535
|
|
|
[5]
|
Patient dosimetry of 177Lu-PSMA I&T in metastatic prostate cancer treatment: the experience in Thailand
Annals of Nuclear Medicine,
2021
DOI:10.1007/s12149-021-01659-8
|
|
|
[6]
|
Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [177Lu]DKFZ-PSMA-617
Molecular Imaging and Biology,
2016
DOI:10.1007/s11307-016-0942-0
|
|
|
[7]
|
How Safe Are Reduced Doses per Fraction in Target Volumes of 2nd to 4th Order in the Simultaneous Integrated Boost Irradiation Technique in Head and Neck Carcinoma Patients?
Journal of Cancer Therapy,
2015
DOI:10.4236/jct.2015.62023
|
|
|